Technical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma
NEW YORK, September 7, 2017 /PRNewswire/ --
If you want a Stock Review on ZIOP, ZSAN, JUNO, or LXRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. The Medical sector, which includes both pharmaceutical/Biotech and medical device companies, recorded earnings growth of 6.7% on revenue growth of 4.2% in Q2 2017, as per a Zacks report. As of August 25th, 2017, the beat ratio for earnings and revenues was 83.3% and 64.8%, respectively, in the quarter under review. In today's pre-market research, DailyStockTracker.com covers the recent performance of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Zosano Pharma Corp. (NASDAQ: ZSAN), Juno Therapeutics Inc. (NASDAQ: JUNO), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
http://dailystocktracker.com/register/
ZIOPHARM Oncology
Shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. saw a drop of 2.17%, ending Wednesday's trading session at $6.31. The stock recorded a trading volume of 1.05 million shares. The Company's shares have gained 5.87% in the last one month, 8.05% over the last three months, and 17.94% on an YTD basis. The stock is trading 7.57% and 1.17% above its 50-day and 200-day moving averages, respectively. Moreover, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have a Relative Strength Index (RSI) of 59.55.
On September 05th, 2017, ZIOPHARM Oncology announced that Laurence Cooper, M.D., Ph.D., CEO, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12th, 2017, at 12:30 p.m. ET in New York. The live audio webcast of the presentation will be available under the Investor Relations section of the Company's website. Visit us today and access your complete report on ZIOP for free at:
http://dailystocktracker.com/registration/?symbol=ZIOP
Zosano Pharma
Fremont, California headquartered Zosano Pharma Corp.'s stock declined 1.35%, closing the day at $0.88 with a total trading volume of 263,331 shares. The Company's shares have advanced 12.31% since the start of this year. The stock is trading 22.78% below its 50-day moving average. Additionally, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients, have an RSI of 40.46.
On August 28th, 2017, Zosano Pharma announced that it has received notification that the US Patent Application (US 15/438,455) was published by the US Patent Office on August 24th, 2017. The application was originally filed on February 21st, 2017. The patent invention has currently pending claims drawn to M207, a system for delivering zolmitriptan for the treatment of migraine using our ADAM technology. The complimentary research report on ZSAN can be accessed at:
http://dailystocktracker.com/registration/?symbol=ZSAN
Juno Therapeutics
On Wednesday, shares in Seattle, Washington headquartered Juno Therapeutics Inc. recorded a trading volume of 4.45 million shares, which was above their three months average volume of 2.49 million shares. The stock ended the day 2.98% lower at $41.41. The Company's shares have surged 36.26% in the past month, 74.50% in the previous three months, and 119.68% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 36.45% and 69.74%, respectively. Furthermore, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have an RSI of 71.11.
On August 31st, 2017, Juno Therapeutics announced that it will present at Citi's 12th Annual Biotech Conference on September 07th, 2017, at 12:00 p.m. ET. The Company will also present at the Morgan Stanley Global Healthcare Conference on September 12th, 2017, at 1:30 p.m. ET. The presentations will feature a business overview and update by Steve Harr, CFO and Head of Corporate Development.
On September 05th, 2017, research firm Wells Fargo reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $35 a share to $54 a share. Register for free on DailyStockTracker.com and download the research report on JUNO at:
http://dailystocktracker.com/registration/?symbol=JUNO
Lexicon Pharmaceuticals
The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s stock declined 0.28%, finishing yesterday's session at $14.41 with a total trading volume of 430,137 shares. The Company's shares have advanced 4.19% on an YTD basis. The stock is trading below its 200-day moving average by 5.76%. Additionally, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 44.53.
On August 15th, 2017, Lexicon Pharma announced additional positive data from the pivotal Phase-3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor. The new data showed that the A1C benefit was sustained over 52 weeks as well as achievement of all secondary endpoints for both sotagliflozin doses. Get free access to your research report on LXRX at:
http://dailystocktracker.com/registration/?symbol=LXRX
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Share this article